Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Q1 Revenues Surge Amid Widened Losses

NEW YORK, April 24 - Ciphergen Biosystems reported a sharp increase in year-over-year revenue for the first quarter today, and widened its losses slightly.

 

The Fremont, Calif., company's revenues for the quarter rose to $12.8 million, from $6.8 million in the first quarter of 2002. The company said the 88 percent revenue surve came from increased sales of its ProteinChip systems and arrays, and its BioSepra process proteomics products; as well as increased service activities.

 

Ciphergen's net losses widened to $9.1 million for the first quarter, from $7.6 million in the year-ago quarter.

 

R&D expenses increased to $6.4 million, from $3.9 million in the first quarter of 2001.

An increase in sales, general, and administrative expenses accounted for the remainder of the rise in expenses to $17.1 million, from $11.8 million in the previous year's period, and consequent widening of losses.

 

As of March 31, Ciphergen had $36.3 million in cash, cash equivalents and investments, compared to $42.5 million at the end of March 2002.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.